Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protalix BioTherapeutics FY 2024 GAAP EPS $0.04 Beats $0.01 Estimate, Sales $53.40M Miss $53.94M Estimate

Author: Benzinga Newsdesk | March 17, 2025 06:00am
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 55.56 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $53.40 million which missed the analyst consensus estimate of $53.94 million by 1.01 percent. This is a 18.47 percent decrease over sales of $65.49 million the same period last year.

Posted In: PLX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist